Kluge R, Körholz D
Universitätsklinikum Leipzig.
Klin Padiatr. 2011 Nov;223(6):315-9. doi: 10.1055/s-0031-1287834. Epub 2011 Oct 19.
The paediatric Hodgkin lymphoma treatment optimisation concepts aim at reduction of treatment intensity with preservation of the high cure rates. A negative interim FDG-PET result after 2 cycles of chemotherapy is associated with a good prognosis. In the current EuroNet-PHL-C1 study radiotherapy is being omitted, if interim PET becomes negative. In addition to the early interim PET after 2 cycles of chemotherapy, all patients undergo an initial PET investigation which is part of the staging processs and plays an essential role for the interpretation of the interim PET. Skeletal involvement can be detected by a typical FDG-PET uptake pattern with high sensitivity and specifity. Therefore, in the forthcoming EuroNet-PHL-C2 study bone marrow biopsy and bone scintigraphy will no longer be part of the staging algorithm.
儿童霍奇金淋巴瘤治疗优化理念旨在在保持高治愈率的同时降低治疗强度。化疗2个周期后氟脱氧葡萄糖正电子发射断层扫描(FDG-PET)结果为阴性与良好预后相关。在当前的欧洲儿童霍奇金淋巴瘤网络-1(EuroNet-PHL-C1)研究中,如果中期PET结果为阴性,则省略放疗。除了化疗2个周期后的早期中期PET外,所有患者均接受初始PET检查,这是分期过程的一部分,对中期PET结果的解读起着至关重要的作用。骨骼受累可通过典型的FDG-PET摄取模式以高灵敏度和特异性检测到。因此,在即将开展的欧洲儿童霍奇金淋巴瘤网络-2(EuroNet-PHL-C2)研究中,骨髓活检和骨闪烁显像将不再是分期算法的一部分。